Clinical Trial Update: Study of VTD in Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the VTD regimen (bortezomib, thalidomide, dexamethasone) for Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoplasmacytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Status: UNKNOWN